Emris Pharma

EMRIS Pharma is developing a first-in-class topical therapy designed to prevent skin toxicities (rash, dryness, irritation) that commonly occur when cancer patients are treated with EGFR-inhibitor antibodies. By delivering protective treatment locally to the skin (instead of systemically), EMRIS aims to help patients stay on their oncology regimen with fewer dose interruptions, better comfort, and improved adherence, while avoiding the side effects that can come with oral or injected supportive meds.